FHL1 and myositis disease: In a subgroup, repeated measurements of the six-item core set measures for evaluation of myositis disease activity were available at baseline for 12 anti-FHL1+ and 6 FHL-; and after 3–5 years for 15 anti-FHL1+ and 9 FHL1− patients with IIM (Table 3).